Literature DB >> 16237564

[Prophylactic surgery of mammary and ovarian carcinoma].

M P Lux1, M R Bani, P A Fasching, M W Beckmann.   

Abstract

New insights into the genetic basis of carcinogenesis have been obtained by modern molecular biological techniques. Several susceptibility genes are known. The hereditary breast and ovarian cancer syndrome (germline mutations in BRCA1 and BRCA2) and endometrial cancer in the context of the hereditary non-polyposis colorectal cancer syndrome (HNPCC), germline mutations in mismatch-repair genes, are the most frequent hereditary cancer syndromes in gynaecology. Mutations in TP53 (Li-Fraumeni syndrome) and PTEN (Cowden's disease), associated with increased risk of breast cancer, are responsible for a smaller portion of familial breast cancer. The risk of inheritance and disease can be identified and defined by investigating family history, risk calculation programs, and genetic testing. Afterwards, options of primary, secondary, and tertiary prevention can be formulated. Presently, prophylactic surgery is the only option proven by clinical trials that can reduce the mortality of hereditary breast and ovarian cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16237564     DOI: 10.1007/s00104-005-1100-4

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  52 in total

1.  Subcutaneous mastectomy with implant reconstruction: cosmetic outcome and patient satisfaction.

Authors:  S K Al-Ghazal; R W Blamey
Journal:  Eur J Surg Oncol       Date:  2000-03       Impact factor: 4.424

Review 2.  Time to reconsider subcutaneous mastectomy for breast-cancer prevention?

Authors:  Kelly A Metcalfe; John L Semple; Steven A Narod
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

3.  Familial invasive breast cancers: worse outcome related to BRCA1 mutations.

Authors:  D Stoppa-Lyonnet; Y Ansquer; H Dreyfus; C Gautier; M Gauthier-Villars; E Bourstyn; K B Clough; H Magdelénat; P Pouillart; A Vincent-Salomon; A Fourquet; B Asselain
Journal:  J Clin Oncol       Date:  2000-12-15       Impact factor: 44.544

4.  Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.

Authors:  Mark Robson; Tiffany Svahn; Beryl McCormick; Patrick Borgen; Clifford A Hudis; Larry Norton; Kenneth Offit
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

5.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

6.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

7.  Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.

Authors:  Pål Møller; Ake Borg; D Gareth Evans; Neva Haites; Marta M Reis; Hans Vasen; Elaine Anderson; C Michael Steel; Jaran Apold; David Goudie; Anthony Howell; Fiona Lalloo; Lovise Maehle; Helen Gregory; Ketil Heimdal
Journal:  Int J Cancer       Date:  2002-10-20       Impact factor: 7.396

8.  Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer.

Authors:  Douglas A Levine; Mark G Federici; Victor E Reuter; Jeff Boyd
Journal:  Gynecol Oncol       Date:  2002-06       Impact factor: 5.482

9.  Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status.

Authors:  J Nathorst-Böös; B von Schoultz; K Carlström
Journal:  J Psychosom Obstet Gynaecol       Date:  1993-12       Impact factor: 2.949

10.  Breast reconstruction: current state of the art.

Authors:  J E Woods
Journal:  Mayo Clin Proc       Date:  1986-07       Impact factor: 7.616

View more
  1 in total

Review 1.  [Genes beyond BRCA1 and BRCA2 for hereditary breast cancer].

Authors:  Katharina Simon; Jochen B Geigl; Gunda Pristauz
Journal:  Wien Med Wochenschr       Date:  2010-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.